Living Creatively With Alzheimer’s: Laura Tobi’s Story

Originally from Argentina, educator and creative entrepreneur Laura Tobi, 58, moved to the U.S. 26 years ago. An educational designer by training, she has worked with labor unions, corporations, government, and public and private school systems, later founding a Miami-based business to cultivate creative thinking for learners of all ages. After years as a caregiver to her both husband and daughter through serious chronic illnesses, she and her husband relocated to North Carolina in 2024, where she noticed increased memory problems. A neurologist connected the dots: a lumbar puncture confirmed Alzheimer’s, and further evaluation found epilepsy, revealing silent seizures. In this interview with Being Patient’s Mark Niu, Tobi shares how she pairs Leqembi infusions with lifestyle changes inspired by the Ornish program — nutrition, exercise, stress management, and social support — while staying rooted in community through volunteering, teaching, improv, and clay sculpture in her home studio. Her takeaways: build community, stay mentally and physically active, advocate for yourself, and keep seeking joy — through teaching, volunteering, improv, and making art.—-If you loved listening to this Live Talk, visit our website to find more of our Alzheimer’s coverage and subscribe to our newsletter: https://www.beingpatient.com/Follow Being Patient: Twitter: https://twitter.com/Being_Patient_Instagram: https://www.instagram.com/beingpatientvoices/Facebook: https://www.facebook.com/beingpatientalzheimersLinkedIn: https://www.linkedin.com/company/being-patientBeing Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia. Check out our latest Live Talks: https://www.beingpatient.com/category/video/

There are no comments yet.

Please log in to write the first comment.